Department of Defense Pharamacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Closed Solicitation Posted
- Solicitation number
- HT9402-25-Q-9303
- Agency
-
Defense Health Agency
Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- San Antonio, Texas 78230, United States
- Points of contact
-
- Tracy Banks tracy.e.banks2.civ@health.mil
- Julianne Canaley julianne.m.canaley.ctr@health.mil
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Health Agency is soliciting quotes for pharmaceutical agents under the Department of Defense Uniform Formulary Blanket Purchase Agreement and Uniform Formulary Additional Discount Program. This procurement supports the DoD's legally mandated integrated pharmacy benefits program for the Military Health System, focusing on five newly approved drugs scheduled for review at the August 2025 Pharmacy and Therapeutics Committee meeting: Hemiclor (diuretics), Symbravo (migraine agents), umeclidinium-vilanterol (COPD treatment), ustekinumab (immunomodulatory biologics), and Vyvgart Hytrulo (neurological agents). The solicitation aims to establish pricing agreements that will help the P&T Committee evaluate both clinical effectiveness and cost-effectiveness of these pharmaceutical agents for potential inclusion in the DoD Uniform Formulary, with classifications ranging from generic to non-formulary status. Key dates include a pre-quotation teleconference on June 4, 2025, and quotes due by June 20, 2025. Pharmaceutical manufacturers must submit detailed pricing information, refund percentages, and clinical effectiveness data, with responses to clinical questions required via email to the designated point of contact.
This solicitation operates without any set-aside designations and does not identify current incumbents or contractors. The procurement covers pharmaceutical agents that would be dispensed through military treatment facilities, TRICARE Mail Order Pharmacy, and the TRICARE retail network, though specific award values or budget ranges are not disclosed in the solicitation materials. The timeline involves a 120-day window for the P&T Committee to recommend tier placement for newly approved drugs, with manufacturers having multiple solicitation windows to submit price concessions. Place of performance is designated as San Antonio, Texas, reflecting the Defense Health Agency's operational headquarters. The solicitation includes detailed pricing spreadsheets for each drug category and comprehensive guidance documents to assist vendors in preparing their submissions for up to 10 National Drug Codes per manufacturer.
Notice text
2 versions
Update #2 · Latest ·
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
P&T COMMITTEE MEETING: The following August 2025 newly approved drugs will be reviewed:
a. Hemiclor - Diuretics - NA
b. Symbravo - Migraine Agents - Triptans
c. umeclidinium-vilanterol - Pulmonary-2 Agents - Chronic Obstructive Pulmonary Disease
d. ustekinumab - Targeted Immunomodulatory Biologics - IL-23
e. Vyvgart Hytrulo - Neurological Agents Miscellaneous - NA
The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-25-Q-9303.
Pre-quotation teleconference is on June 4, 2025. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.
Update #1 ·
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
P&T COMMITTEE MEETING: The following August 2025 newly approved drugs will be reviewed:
a. Hemiclor - Diuretics - NA
b. Symbravo - Migraine Agents - Triptans
c. umeclidinium-vilanterol - Pulmonary-2 Agents - Chronic Obstructive Pulmonary Disease
d. ustekinumab-Centocor - Targeted Immunomodulatory Biologics - IL-23
e. Vyvgart Hytrulo - Neurological Agents Miscellaneous - NA
The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-25-Q-9303.
Pre-quotation teleconference is on June 4, 2025. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.
Files
| File | Type | Posted |
|---|---|---|
| A-1 Price List - ustekinumab - TIBs - IL-23.xlsx | XLSX spreadsheet | |
| Amendment 01 RFQ2 NAD.pdf | ||
| Price List - umeclidinium-vilanterol - Pulmonary-2 Agents - COPD.xlsx | XLSX spreadsheet | |
| RFQ HT9402-25-Q-9303 NAD.pdf | ||
| Price List - Symbravo - Migraine Agents - Triptans.xlsx | XLSX spreadsheet | |
| Price List - ustekinumab-Centocor - TIBs - IL-23.xlsx | XLSX spreadsheet | |
| Price Appendix FAQ NAD.pdf | ||
| DoD Formulary Placement of FDA Newly Approved Drugs.pdf | ||
| Price List - Hemiclor - Diuretics - NA.xlsx | XLSX spreadsheet | |
| Price List - Vyvgart Hytrulo - Neurological Agents Misc - NA.xlsx | XLSX spreadsheet |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity